US Patent Issued to Bristol-Myers Squibb on Jan. 20 for "Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody" (New Jersey Inventor)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,528,865, issued on Jan. 20, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody" was invented by Faith Nathan (Moorestown, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereo...